Epizyme parts ways with its CEO ahead of big Phase II cancer bet

After more than 5 years in the top spot, Epizyme ($EPZM) CEO Robert Gould is stepping down next month, leaving the company as it presses forward with a pair of promising cancer drugs. Gould will leave the post Sept. 10, maintaining a seat on the board as he is replaced by Robert Bazemore, who served as chief operating officer of Synageva until Alexion Pharmaceuticals ($ALXN) bought it for $8.4 billion last month. Meanwhile, Epizyme is advancing two treatments for blood cancers, hoping to replicate positive Phase I results in mid-stage trials. Release

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.